Israel’s Compugen (see here previously) only had six months’ cash left when it was rescued by Gilead Sciences in a deal worth up to $848 million. Gilead will license Compugen’s pre-clinical cancer antibody COM503 that frees up the peptide InterLeukin 18 (IL-18) to destroy tumors.

https://www.calcalistech.com/ctechnews/article/b1ue00g1wa